Kaitlyn D’Onofrio

DocwireNews

A study evaluated the predictive value of a <a href="https://www.docwirenews.com/docwire-pick/hem-onc-picks/ai-algorithm-outperforms-radiologists-in-detecting-breast-cancer/">machine learning</a> algorithm to forecast 180-day mortality in cancer patients in the outpatient oncology setting.
“<a href="https://www.docwirenews.com/docwire-pick/ai-generates-mri-super-images-greatly-improves-brain-imaging/">Machine learning (ML)</a> algorithms can identify patients with cancer at risk of short-term mortality to inform treatment and advance care planning. However, no ML mortality risk prediction algorithm has been prospectively validated in oncology or compared with routinely used prognostic indices.”
The study included cancer patients with outpatient oncology visits between March 1, 2019, and April 30, 2019. The machine learning algorithm was employed to predict 180-day mortality risk between four and eight days ahead of the patient encounter, which took place at either a tertiary practice (n=1) or general oncology practice (n=17). Patients aged 18 years or older were eligible for inclusion. They were excluded if their appointment was scheduled after the creation of weekly predictions and if their evaluation only took place in benign hematology, palliative care, or rehabilitation practices.
The machine algorithm that predicted mortality was trained using “retrospective data from a subset of practices,” the researchers shared. The main outcome of the study was mortality within 180 days of the visit, with the area under the curve receiver operating characteristic curve (AUC) used as the primary performance metric.
A total of 24,582 patients were seen during the study period; 1,022 (4.2%) died during the 180-day period following their appointment. Among the total cohort, the median (interquartile range) age was 64.6 (53.6–73.2) years, and nearly two-thirds (n=15,319; 62.3%) were female. For the whole study group, the AUC was 0.89 (95% confidence interval [CI], 0.88 to 0.90). The AUC varied by disease at the tertiary practice, ranging from 0.74 to 0.96. The predetermined mortality risk threshold to separate high- versus low-risk patients was 40%. From this benchmark, the observed 180-day mortality in the high-risk group was 45.2% (95% CI, 41.3% to 49.1%) and the low-risk group was 3.1% (95% CI, 2.9% to 3.3%).
The authors observed that “Integrating the [machine learning] algorithm into the Eastern Cooperative Oncology Group and Elixhauser comorbidity index–based classifiers resulted in favorable reclassification (net reclassification index, 0.09 [95% CI, 0.04-0.14] and 0.23 [95% CI, 0.20-0.27], respectively).”
The research was reported in <a href="https://jamanetwork.com/journals/jamaoncology/article-abstract/2770698">JAMA Oncology</a>.
The authors of an <a href="https://jamanetwork.com/journals/jamaoncology/article-abstract/2770694">invited commentary</a> said that the study “represents an important early step in health care [machine learning], though there remains a long road ahead for the field.”

Rob Dillard

A Western Diet During Pregnancy May Increase the Risk of ADHD

Neurodivergent

Babak J. Orandi, MD, PhD

Charlotte Robinson

GLP-1 Agonists Benefit Kidney Transplant Recipients With T2D

Kidney Transplantation

Food Insecurity Associated With Cardiovascular Disease

Preventive Cardiology

Latest News

Machine Learning Algorithm Predicts Short-Term Cancer Mortality in Outpatients

Oncology

A study evaluated the predictive value of a machine learning algorithm to forecast 180-day mortality in cancer patients in the outpatient oncology setting. ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Metabolic Acidosis

Nephrology Times

Mesothelioma

Non-Small Cell Lung Cancer

Small Cell Lung Cancer

Lung Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Sleep

Urology

Diabetes

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe